Ductal Carcinoma In Situ of the Breast: Perspectives on Tumor Subtype and Treatment

Table 2

Cox proportional hazards regression model analysis of overall survival (OS) and breast cancer-specific mortality (BCSM).

Variables	OS		BCSM
	aHR (95% CI)	P value	aHR (95% CI)	value
Age at diagnosis (y)
<35	Reference		Reference
35-49	564.1 (0.0, 1.49E58)	0.922	5.092 (0.0, 1.58E177)	0.994
50-64	550.8 (0.0, 1.45E58)	0.923	1591.7 (0.0, 3.37E179)	0.972
≥65	3134.5 (0.0, 8.24E58)	0.902	8686.1 (0.0, 1.84E180)	0.965
Grade
Well	Reference		Reference
Moderately	4.965 (0.647, 38.096)	0.123	2275.2 (0.0, 3.711E22)	0.732
Poorly	1.318 (0.158, 11.018)	0.799	3735.7 (0.0, 6.985E22)	0.716
Undifferentiated	2.882 (0.243, 34.136)	0.401	69.918 (0.0, 1.380E30	0.898
Laterality
Left	Reference		Reference
Right	1.913 (0.983, 3.724)	0.056	14.934 (0.685, 325.57)	0.086
Tumor size (mm)
≤10	Reference		Reference
10-20	1.411 (0.602, 3.307)	0.428	0.003 (0.0, 2405831.4)	0.579
20-50	0.633 (0.172, 2.338)	0.493	0.138 (0.003, 7.196)	0.327
>50	1.750 (0.445, 6.888)	0.423	0.267 (0.009, 7.787)	0.443
Subtype
HoR+/HER-	Reference		Reference
HoR+/HER+	1.269 (0.480, 3.354)	0.630	1.595 (0.083, 13.188)	30.732
HoR-/HER+	2.518 (0.2918, 6.909)	0.073	0.365 (0.007, 17.853)	0.611
TN	3.878 (1.619, 9.289)	0.002	17.093 (0.467, 625.28)	0.122
Radiotherapy
No	Reference		Reference
Yes	0.261 (0.083, 0.891)	0.021	3.751 (0.110, 127.66)	0.463
Local treatment
M	Reference		Reference
BCS	1.274 (0.512, 3.171)	0602	0.0 (0.0, 4.739E42)	0.886
BCS+R	0.270 (0.101, 0.718)	0.009	0.001 (0.0, 1.492E18)	0.764
Surgery
M+ALND	Reference		Reference
M+SLNB	0.5484 (0.236, 1.275)	0.163	0.014 (0.001, 0.389)	0.012
BCS+ALND	0.891 (0.170, 4.666)	0.891	0.0 (0.0)	0.984
BCS+SLNB	0.265 (0.099, 0.705)	0.008	0.0 (0.0, 2.337E178)	0.945

values calculated by Log-rank testing; bold if statistically significant, . M: mastectomy; BCS: breast-conserving surgery; R: radiotherapy; HoR: hormone receptor; TN: triple negative; LN: lymph node; SLNB: sentinel lymph node biopsy; ALND: axillary lymph node dissection. aHR: adjusted hazard ratio (adjusted for age at diagnosis, race, grade, tumor size, laterality, ER, PR, HER2, subtype, radiotherapy, local treatment, and surgery).